Treatment for congenital toxoplasmosis: finding out what works.
Evidence for the effectiveness of prenatal or postnatal treatment for congenital toxoplasmosis will be critical to guide policy about prenatal and neonatal screening over the next 10 years, let alone the next 100. Randomised controlled trials are needed to address questions about treatment effectiveness, although cohort studies are also needed to provide information on prognosis, especially disability. Nowhere are such studies needed more than in South America where congenital toxoplasmosis is a major public health problem.
Gilbert
Ruth
R
Centre for Paediatric Epidemiology and Biostatistics, UCL, Institute of Child Health, London, UK. r.gilbert@ich.ucl.ac.uk
D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007231:Infant, Newborn; D015997:Neonatal Screening; D011296:Prenatal Diagnosis; D014125:Toxoplasmosis, Congenital / Q000175:diagnosis / Q000188:drug therapy*
D000981:Antiprotozoal Agents